Adagene Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Adagene is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $2.44, 49.0% below its 52-week high and below its 200-day average, which is rising.

$2.44

+0.41% today

$164M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ADAG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 19w

S4 29w

S2 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 8w → S1 7w → S2 19w → S3 11w → S2 7w → S3 4w → S4 7w → S1 3w → S4 29w → S1 9w → S2 9w → S3 5w → S4 9w → S1 1w → S2 19w → S3 4w → S2 9w → S3 5w → S4 1w current

Total tracked: 166 weeks across 19 stage runs.

ADAG among Biotechnology120th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…120	ADAGAdagene Inc.	Stage 4 · wk 2	76	−17.8%

vs 52W High

-49.0%

$1.41 lo$4.78 hi

49.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-28.2%

200 DMA: $3.40 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.83x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-17.8%

-23.8%

-34.8%

YTD

+32.6%

+29.1%

Scan Membership

Breakout Watch

Latest: 2024-06-27

3 appearances in last 60 days. First seen: 2023-02-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.83x

2026-10-21S4

Wk 1 · Vol 0.31x

2026-10-20S4

Wk 1 · Vol 0.30x

2026-10-19S4

Wk 1 · Vol 1.01x

2026-10-16S4

Wk 1 · Vol 1.25x

2026-10-15S43→4

Wk 1 · Vol 1.83x

2026-10-14S3

Wk 5 · Vol 3.14x

2026-10-13S3

Wk 5 · Vol 0.81x

2026-10-12S3

Wk 5 · Vol 0.77x

2026-10-09S3

Wk 5 · Vol 6.55x

2026-10-08S3

Wk 4 · Vol 0.94x

2026-10-07S3

Wk 4 · Vol 0.67x

Moving averages & range

50 DMA

$3.22

200 DMA

$3.40

52W High

$4.78

52W Low

$1.41

5D Low

$2.06

Resistance levels (recent highs)

20d High

$3.21

60d High

$4.23

120d High

$4.78

250d High

$4.78

Next resistance

+31.6%

to 20d High

ROE

-28.5%

Profit margin -220.8%

Dividend Yield

0.00%

P/B 1.8

Adagene: quick answers

What stage is Adagene in?

As of Oct 22, 2026, Adagene (ADAG) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Adagene in an uptrend?

No. Adagene is in a Stage 4 downtrend. It trades 28.2% below its 200-day average, which is rising.

How far is Adagene from its 52-week high?

Adagene closed at $2.44 on Oct 22, 2026, 49.0% below its 52-week high of $4.78. Its 52-week low is $1.41.

How has Adagene performed over the past year?

As of Oct 22, 2026, Adagene is up 29.1% over the past year and up 32.6% so far in 2026.

Which sector and industry is Adagene in?

Adagene is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.